Literature DB >> 6141780

Chemistry, physiology and neuropsychology of schizophrenia: towards an earlier diagnosis of schizophrenia I.

H H Kornhuber.   

Abstract

Data supporting the glutamate hypothesis of schizophrenia are presented. The glutamate hypothesis is linked to the dopamine hypothesis by the fact that dopamine synapses inhibit the release of glutamate in the striate and mesolimbic system. The glutamate hypothesis of schizophrenia may open a way to find better drugs for treatment. The concept of schizophrenia I is described. It consists of "negative symptoms" such as disconcentration or reduction of energy. Schizophrenia I precedes and follows schizophrenia II with "positive symptoms," e.g. hallucinations and delusions. Schizophrenia I so far cannot be diagnosed as schizophrenia unless schizophrenia II appears. Chemical, physiological or neuropsychological methods for the diagnosis of schizophrenia I would render an earlier treatment of schizophrenia possible and thus make social and occupational rehabilitation more efficient. An objective diagnosis of schizophrenia I may also elucidate the mode of genetic transmission of schizophrenia. Several neuropsychological methods distinguish schizophrenic patients as a group from normals. Some of them are based on a specific disturbance of long term concentration. The EEG also distinguishes schizophrenics from normals when analyzed during voluntary movement. For schizophrenics it takes more effort to initiate a voluntary movement, and there are several features of the EEG correlated to this. Moreover, the longer motor reaction time of schizophrenics is paralleled by a longer duration of the Bereitschaftspotential in schizophrenia. Furthermore, there is a difference in the theta rhythm between schizophrenic patients and normals in a task which requires concentration. Some of the children of schizophrenic parents show a disturbance of concentration in both reaction time tasks and the d 2 test.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6141780     DOI: 10.1007/bf00342782

Source DB:  PubMed          Journal:  Arch Psychiatr Nervenkr (1970)


  24 in total

1.  The brain's dopamine receptor: labeling with (3H) dopamine and (3H) haloperidol.

Authors:  S H Snyder; I Creese; D R Burt
Journal:  Psychopharmacol Commun       Date:  1975

2.  Warned reaction times of manic-depressive patients with and without lithium.

Authors:  K Pfeiffer; I Maltzman
Journal:  J Abnorm Psychol       Date:  1976-04

3.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

4.  The early symptoms of schizophrenia.

Authors:  J Chapman
Journal:  Br J Psychiatry       Date:  1966-03       Impact factor: 9.319

5.  The free amino acids in human cerebrospinal fluid.

Authors:  M van Sande; Y Mardens; K Adriaenssens; A Lowenthal
Journal:  J Neurochem       Date:  1970-02       Impact factor: 5.372

6.  [Kornhuber's phenomenon in schizophrenics and borderline cases].

Authors:  M Timsit
Journal:  Rev Neurol (Paris)       Date:  1970-06       Impact factor: 2.607

7.  Axo-axonic synapses in the rat striatum.

Authors:  J Kornhuber; M E Kornhuber
Journal:  Eur Neurol       Date:  1983       Impact factor: 1.710

8.  Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction.

Authors:  T L Perry
Journal:  Neurosci Lett       Date:  1982-01-22       Impact factor: 3.046

9.  Disturbed smooth pursuit and saccadic eye movements in schizophrenia.

Authors:  W Schmid-Burgk; W Becker; V Diekmann; R Jürgens; H H Kornhuber
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1982

10.  Cerebral glutamate, neuroleptic drugs and schizophrenia: increase of cerebrospinal fluid glutamate levels and decrease of striate body glutamate levels following sulpiride treatment in rats.

Authors:  J S Kim; D Claus; H H Kornhuber
Journal:  Eur Neurol       Date:  1983       Impact factor: 1.710

View more
  2 in total

1.  Impairment of perception and recognition of faces, mimic expression and gestures in schizophrenic patients.

Authors:  K Berndl; M von Cranach; O J Grüsser
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1986

2.  Intrastriatal injection of DL-2-amino-5-phosphonovaleric acid (AP-5) induces sniffing stereotypy that is antagonized by haloperidol and clozapine.

Authors:  W J Schmidt
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.